您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CP 31398 dihydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CP 31398 dihydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CP 31398 dihydrochloride图片
CAS NO:1217195-61-3
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
CP 31398 dihydrochloride 可稳定 p53 的活性构象并促进具有突变型或野生型 p53 的癌细胞系中的 p53 活性。
Cas No.1217195-61-3
化学名(E)-N1-(2-(4-methoxystyryl)quinazolin-4-yl)-N3,N3-dimethylpropane-1,3-diamine dihydrochloride
Canonical SMILESCN(C)CCCNC1=C2C=CC=CC2=NC(/C=C\C3=CC=C(OC)C=C3)=N1.Cl.Cl
分子式C22H26N4O.HCl
分子量435.39
溶解度<43.54mg/ml in DMSO;<43.54mg/ml in Water
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

CP 31398 dihydrochloride is a potent activator of p53 with maximum tolerated dose of 400 ppm [2].

Tumor protein p53 (p53) is a crucial protein in multicellular organisms and plays an important role in preventing cancer formation. Many studies have shown that activated p53 regulates the expression of p21 which binds to the G1-S/CDK complexes (molecules important for the G1/S transition in the cell cycle) and inhibits their activity [1].

CP 31398 dihydrochloride is a potent p53 stabilization and is regarded as a promising agent which combines with chemotherapy drugs for cancer treatment. When tested with a panel of 9 human cancer cell lines, CP 31398 dihydrochloride treatment resulted in cell apoptosis in mutant or wild-type p53 expressed cell lines (SW480, SKBr3, PA1, U20S, HCT116, and Saos-2) and enhanced chemotherapeutic drugs effect on cell killing while had no effect on cell lines not expressed p53 [1]. In four human HNSCC cell lines (JHU-O29, UMSCC-22A and Fadu), administration of CP 31398 dihydrochloride for 96 h inhibited the cell growth by accumulating p53 expression [2].

In colon adenocarcinomas F344 rast model, combination low dose of CP 31398 dihydrochloride with celecoxib markedly suppressed colon adenocarcinoma incidence (78%) and multiplicity (90%) by enhancing the expression of p53 which indicated that a combination of low dose CP-31398 dihydrochloride and celecoxib could be a promising therapy for colon cancer in clinic [3].

References:
[1].  Takimoto, R., et al., The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther, 2002. 1(1): p. 47-55.
[2].  Roh, J.L., et al., p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol, 2011. 47(1): p. 8-15.
[3].   Rao, C.V., et al., Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res, 2009. 69(20): p. 8175-82.